• news-blogs-banner
  • UTHEVER®NMN awarded 2020 Top 10 Hot raw materials in the nutrition and health industry
    2020-11-23 UTHEVER®NMN awarded 2020 Top 10 Hot raw materials in the nutrition and health industry
    2020 Nutrition Health Entrepreneur Conference (NHEC) was hosted in Bejing International Conference center on Nov.22nd, 2020. With the theme of "Embracing the Future of change and Win-win," this annual conference brings together leaders from national ministries and commissions, authoritative experts in the nutrition and health industry, and top entrepreneurs from the global-wide health industry. It provides "decision-making" and "connection" support for developing China's future nutrition industry through forward-looking and systematic industrial information exchange. Since professor David Sinclair and other international scientists confirmed that NMN is available to make 22 months mice body back to 6 months (the equivalent of human from 60 to 20 years younger), NMN has aroused attention from Different industries. And the triggered marketing potential makes the quality of NMN raw material uneven. And in this context, Effepharm stands out and use the standard of pharmaceutical R&D and USP guidance to provide more reliable, more affordable, healthy ingredients for worldwide clients. UTHEVER® is also the only NMN manufacture which conducted clinical trials so far. The brand NMN raw material UTHEVER® launched by Effepharm has successfully improved the original NMN extraction process and significantly improved the quality of NMN material's density and stability. Therefore, among the many declared…
  • NMN studies revealed that NMN may imparts protection against Doxorubicin-induced cardiotoxicity
    2020-11-11 NMN studies revealed that NMN may imparts protection against Doxorubicin-induced cardiotoxicity
    Recently, the WHO and IARC released the latest World Cancer Report, which provides a comprehensive overview of the global burden of increasing cancer-incidence, risk factors, and biological processes of cancer and prevention measures. Cancer has already become the second leading cause of death globally, while the number of cases still revealed with an increasing trend year by year. The World Health Organization (WHO) estimates that the number of cancer cases worldwide is likely to increase by 60% more in the next 20 years. Doxorubicin (DOX) has been used as a first-line treatment for cancer and is a non-negligible revenue player for the pharmaceutical industry. Because of its toxicity and bright red appearance, Doxorubicin has long had a frightening nickname: Red Devil. In addition to most chemotherapy antibiotics’ common side effects such as nausea, vomiting, canker sores, and hair loss, DOX can also cause acute and chronic heart toxicity, which can be almost fatal.Previous studies have shown that doxorubicin (DOX) blocks the autophagic flux in cardiomyocytes by inhibiting lysosome acidification. The V-ATPase pump maintains the acidic pH of lysosomes. However, DOX treatment also significantly depletes the NAD+ levels in cardiomyocytes.Therefore, the study conducted by The University of Western Ontario investigated NMN’s…
  • Effepharm Won the 2020 “NEW POWER” Innovation Award For the NMN Brand Material UTHEVER®
    2020-10-27 Effepharm Won the 2020 “NEW POWER” Innovation Award For the NMN Brand Material UTHEVER®
    Asiaceutical Summit & Expo 2020 took place in Guangzhou from October 21st to 23rd. This conference was hosted by the Herbridge, which gathered the experts in foods, beverage and health care industry. Experts provided cutting edge perspectives under the circumstances of coronavirus, 5G technology commercialization, and new form of the natural health industry. Other industry-leading companies also participated in this conference, such as Byhealth, Wahaha, and Effepharm.Ltd. This expo aims to encourage brand innovation and development, share new perspectives on food and drug technology, open up new ideas for research and development, and find the capital investment for future unicorn companies.  During the prize-award ceremony, Effepharm stood out and won the “New Power” Innovation Award voting by new health product raw material evaluation experts, R&D department, and capital side. Chief regulatory officer of Effepharm, Hank Huang, delivered a speech on UTHEVER®NMN “Longevity medicine” at the expo. Staying young and keeping energetic have always been the top hottest topics among scientific and healthcare communities. It is also the proposition which the medical industry always desires to conquer. Effepharm has been dedicated to research and develop NMN’s function of anti-aging and antioxidant since 2016. In virtue of the cooperation’s unique conveying system platform…
  • Meet us at Asiaceutical Summit & Expo 2020
    2020-09-30 Meet us at Asiaceutical Summit & Expo 2020
    From 21Oct to 23Oct 2020, Effepharm will attend Asiaceutical Summit & Expo 2020 in Guangdong, China. As an exhibitor, our booth will be B17. At the expo, Effepharm will introduce its next-generation NMN - UTHEVER® to our customers and the public. At 14:00, 22Oct2020, our Director of Scientific and Regulatory Affairs will be addressing a keynote speech on the history, development, and future of NMN. Looking forward to meeting you at Asiaceutical Summit & Expo 2020.
  • A new PCT patent of UTHEVER® NMN filed by Effepharm recently
    2020-09-10 A new PCT patent of UTHEVER® NMN filed by Effepharm recently
    Effepharm recently filed a new PCT patent of UTHEVER® NMN . The following is the patent details.The patent is an application of nicotinamide mononucleotide in preparation of reagent for increasing Na+- K+- ATPase level in damaged skin muscle membrane. The invention relates to the technical field of medicine, and provides the application of nicotinamide mononucleotide in the preparation of a reagent for increasing the Na+-K+-ATPase level in the muscle membrane of damaged skin. Through UVB-induced mouse skin injury model experiments, nicotinamide mononucleotide can increase the activity of Na+-K+-ATPase in the skin, thereby maintaining the normal sodium-potassium pump that damages the skin muscle membrane; it can improve serum, skin and liver It can reduce the oxidative stress damage induced by UVB irradiation; at the same time, it can inhibit the pro-inflammatory cytokines TNF-α, IL-1β and IL-6 and increase the anti-inflammatory cytokines IκB-α, IL- The activation of 4 and IL-10 ultimately reduces the body’s inflammatory damage, thereby providing a basis for the development of NMN-related drugs, health foods or cosmetics that improve skin aging and damage, and improve the body’s antioxidant capacity. Effepharm has taken another great step in the cause of human health and anti-aging, so that more people can benefit from…
  • Sales Office transferred to Shanghai
    2020-07-08 Sales Office transferred to Shanghai
    Sales Office transferred to Shanghai The sales office was transferred to Shanghai in 2017-EffePharm(Shanghai)Co.,Ltd At Effepharm, we apply science and technologies to improve health and well-being at every stage of life with innovative thinking. Our dedicated team strive to set the standard for quality, safety and value in the discovery, development and manufacturing of health ingredients for people. Sparing no effort to deliver more reliable and affordable health ingredients around the world, Effepharm is making a difference for all who rely on us.
  • Meet Us at the Vitafoods Europe 2019!
    2020-07-08 Meet Us at the Vitafoods Europe 2019!
      May. 2019, Effepharm teams will participate in Vitafoods Europe 2019 Exhibit, a annual event where the global  nutraceutical supply chain come to gether to do business At that time, Effepharm teams will be waiting for your inquiry and cooperation in booth of Sliver Area No. N189. Effepharm’s booth location diagram is as follows. EffePharm (Shanghai) Co., Ltd is a scientific and technological innovation company focusing on developing and producing health-care products, pharmaceutical intermediates and nutritional ingredients. In this exhibition, we will show the latest research and development achievements. We believe that you are have a nice experience and deep impression on our products and service. We are looking forward to your coming!
  • New Laboratory has been completed!
    2020-07-08 New Laboratory has been completed!
    Effepharm Ltd. currently not only holds a strong R&D team consisting of experienced  PHDs and Postdocs returned from abroad, but also employs senior professors and  scholars at home and abroad as a team of research consultants to help us optimize  production applications. Effepharm owns HPLC, GC, infrared, ultraviolet and other conventional testing  equipment, and signs a long-term cooperation agreement with professional testing  institutions to ensure the testing timeliness of the company's products. From requirements submitting to product delivered, Effepharm has comprehensive product preparation capabilities from small, pilot to scale-up production as a one-stop stop provider.
  • Effepharm team in the Vitafoods Europe 2019
    2020-07-08 Effepharm team in the Vitafoods Europe 2019
    On 7th May, 2019, Sales team at Effepharm came to vitafoods with latest products and new technology. Booth Position:Sliver Area  No. N189 NMN- Popular NAD+ Precursors CBD- This ingredient is very popular in many Europe countries. Effepharm’s R&D has scheduled to devote more efforts into this ingredient development. That would be one outbreaking ingredient in supplement industry. At Vitafoods, we also showcased our IDS, many audiences have plenty of interests into this as they also bring the problems of their own products such as low bioavailability, poor taste... Our IDS aka Ingredients Delivery System Platform, is engineered technology for the targeted delivery higher bioavailability and/or controlled release of ingredients to achieve a nutraceutical effect in humans or animals, which can solve problems of our customers and custom ingredients for them. We met many old friends from all around the world and attracted more customers to cooperate with us based on new ingredient and innovative technologies.
  • Effepharm team at ”Hi Japan”
    2020-07-08 Effepharm team at ”Hi Japan”
    From 2nd to 4th Oct 2019, Effepharm team participated in Hi Japan Exhibit, the Largest Trade Show for Functional & Health Ingredients in Japan. Effepharm is in line with the purpose of this event. Its Highlights: not only the food industry but also cosmetics, pharmaceuticals and proposal of development of high added value food with appealing point of health function. Effepharm introduced the main product NMN to new customers and cooperated with them based on new ingredients and innovative technologies. Also we met many old friends from all around the world, we were looking forward to have further Cooperation.
  • Effepharm announced acquisitions and new R&D center establishment
    2020-07-08 Effepharm announced acquisitions and new R&D center establishment
    Effepharm acquired two bio-pharmaceutical companies recently, named Dendrimer Co. and Folvo Co., the acquisition has significantly enhanced our R&D capability in anti-aging and energy metabolism. Also Effepharm’s new R&D center is established. Effepharm’s new R&D center will focus on new pharmaceutical and dietary ingredient development by means of plant extraction, fermentation and synthesis, etc. It is expected to open in Mar 2020 with more than 1400 square meters and a total investment of over 5 million USD. Besides facilitating new instruments and equipments, the R&D center will include 2 conference rooms, which will be used for training the customers as well as general public. Effepharm is thrilled to tell you the big news. And the news is reported by Businesswire and other newspapers. For more information, visit https://www.businesswire.com/news/home/20191212005222/en/Effepharm-Announced-Acquisitions-New-Center-Establishment
  • Clinical evidence on the safety of NMN released recently
    2020-07-08 Clinical evidence on the safety of NMN released recently
    Researchers from Keio University and Washington University published a new article on Endocrine Journal. The safety of single dose at 100, 250, and 500 mg NMN was investigated in 10 Japanese men. Clinical findings and parameters, and the pharmacokinetics of NMN metabolites were investigated for 5 h after each intervention. The study concluded that the single oral administration of NMN was safe and effectively metabolized in healthy men without causing any significant deleterious effects. Thus, the oral administration of NMN was found to be feasible, implicating a potential therapeutic strategy to mitigate aging-related disorders in humans[1]. The study is just the start of a series of clinical studies on NMN and it proved NMN’s safety to some extent. However, due to the lack of a control group and the small sample size, further studies will be needed. Besides, the safety of repeated-dose on humans remains to be confirmed. The clinical study on UTHEVERTM would somehow further confirms NMN’s safety on repeated dose with placebo group. The sample size would be 66 which is more convincing. Reference Junichiro Irie, etc. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men, Endocine Journal, 2020, 67 (2), 153-160
1 2 3 4 5

Schedule an Appointment with EffePharm's Experts

+86(021)5770 9202
deal@effepharm.com
Contact Us
Need live support?
Chat with us now